Loading…
Weigao Group subsidiary making dialysis and blood-purification consumables like dialyzers and blood tubing.
Weigao Group subsidiary making dialysis and blood-purification consumables like dialyzers and blood tubing.
Sells single-use items that each dialysis session consumes, so demand repeats for as long as patients are treated, usually several times a week. Hospital purchasing tenders set how much it sells and at what price, and the Weigao group's network helps it reach hospitals.
In one line: A Chinese Fresenius Medical Care/Baxter dialysis-consumables maker.
Moat: narrow (installed base, regulatory licence). Weigao's hospital distribution scale and device registrations support incumbency.
Headquarters: Weihai, Shandong, China · Employees: 3,734
Size Shandong Weigao Blood Purification Products (603014.SS) is a China Health Care company (Medical Specialties) with a market value of $3.63B, the 709th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥34.86 on 6 Nov 2026.
Performance Over six months the shares fell 3.0%, against +6.2% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 4.0% over the last twelve months (peer median +3.6%).
Valuation It trades at 20.4× forward earnings against a peer median of 20.6× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.31B | CN¥3.75B | CN¥3.60B | CN¥3.53B | CN¥3.43B |
| Revenue growth | — | +4% | +2% | +3% | — |
| Gross profit | n/a | CN¥1.41B | CN¥1.43B | CN¥1.44B | CN¥1.37B |
| EBITDA | n/a | CN¥778M | CN¥703M | CN¥601M | CN¥562M |
| Net income | CN¥665M | CN¥482M | CN¥449M | CN¥442M | CN¥315M |
| Free cash flow | CN¥1.09B | CN¥665M | CN¥449M | CN¥56.2M | CN¥467M |
| Capital expenditure | CN¥200M | CN¥160M | CN¥179M | CN¥233M | CN¥280M |
| Total debt | CN¥181M | CN¥2.93M | CN¥67.6M | CN¥34.7M | CN¥134M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Weigao Blood Purification Products 603014.SS | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% |
| Fresenius Medical Care FME.DE | $12.6B | +14% | 0% | 11% | 10.4× | -3.6% |
| Baxter International BAX | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% |
| Jafron Biomedical 300529.SZ | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603014.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.3% | +7.3% | 5th highest of 21 |
| 6-month return | -3.0% | +6.2% | 8th lowest of 21 |
| Distance from 52-week high | -28.9% | -22.0% | 10th lowest of 21 |
| Revenue growth (TTM) | +4.0% | +3.6% | 10th highest of 19 |
| Forward P/E | 20.4× | 20.6× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -1.2% | 10.1% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +8.1% | +7.6% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -9.3 pp | +1.1 pp | 2nd least demanding of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |